FCDC Action Center
Unlock timely coverage and expert-driven perspectives from the Fall Clinical Dermatology Conference (FCDC) in the FCDC Action Center. From emerging therapies in psoriasis and atopic dermatitis to innovations in acne, rosacea, and aesthetic dermatology, this dedicated series keeps you connected to the most relevant updates shaping today’s treatment landscape.
1-11 of 11
The Burden of Itch in Pediatric Atopic Dermatitis
DermConsultThe Burden of Itch in Pediatric Atopic Dermatitis
Mariam Iqneibi, MD
Breaking the Itch-Scratch Cycle in Pediatric Atopic Dermatitis
DermConsultBreaking the Itch-Scratch Cycle in Pediatric Atopic Dermatitis
Mariam Iqneibi, MD
Setting Expectations for Topical JAK Inhibitor Therapy in Atopic Dermatitis
DermConsultSetting Expectations for Topical JAK Inhibitor Therapy in Atopic Dermatitis
Andrew Mastro, MS, PA-C
Closing Gaps in Atopic Dermatitis Treatment Across the Lifespan
DermConsultClosing Gaps in Atopic Dermatitis Treatment Across the Lifespan
Andrew Mastro, MS, PA-C
Tina Bhutani, MD, MAS
Tina Bhutani, MD, MAS
- advertisement
TYK2 Inhibition with Zasocitinib Delivers Early Benefit Across PsA Domains
DermConsultTYK2 Inhibition with Zasocitinib Delivers Early Benefit Across PsA Domains
Rewriting the Rules of Psoriasis Severity: A Global Shift Toward Impact-Driven Care
FCDC Action CenterRewriting the Rules of Psoriasis Severity: A Global Shift Toward Impact-Driven Care
How Systemic Psoriasis Therapies Influence the Risk of New or Recurrent MACEs
FCDC Action CenterHow Systemic Psoriasis Therapies Influence the Risk of New or Recurrent MACEs
Improving Psoriatic Disease Care Through Dermatology–Rheumatology Clinics
FCDC Action CenterImproving Psoriatic Disease Care Through Dermatology–Rheumatology Clinics
Eric Ruderman, MD
Combination Therapy for Plaque Psoriasis: A Reappraisal of Cyclosporine and Acitretin
FCDC Action CenterCombination Therapy for Plaque Psoriasis: A Reappraisal of Cyclosporine and Acitretin
- advertisement